Could lowering insulin help fight fatty liver? new study tests diazoxide

NCT ID NCT07403604

Recruiting now Knowledge-focused Sponsor: Columbia University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage trial is testing whether a one-week course of diazoxide can reduce the production of new fat in the liver. The study involves 25 adults with obesity, insulin resistance, and fatty liver disease. Participants will take either the drug or a placebo and undergo blood tests and insulin suppression tests to measure changes in liver fat production and other metabolic markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: diazoxide (oral suspension)
What this could lead to: If successful, this study could point toward a new way to treat fatty liver disease by lowering insulin levels.
What could go wrong: This is a very early phase 1 trial with only 25 participants, so results may not apply to everyone. The drug may not reduce liver fat or could cause side effects like fluid retention or low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERINSULINEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperinsulinism Insulin Resistance metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERINSULINEMIA INSULIN RESISTANCE NON-ALCOHOLIC FATTY LIVER DISEASE OBESITY PREDIABETIC STATE

Contacts and locations

Locations

Columbia University Irving Medical Center
RECRUITING

New York, New York, 10032, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.